Compare Pfizer Inc (PFE) vs SiTime Corporation (SITM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs SiTime Corporation — how do they compare? Pfizer Inc trades at $27.74 (market cap $159.59B), while SiTime Corporation trades at $654.38 (market cap $19.99B). The key difference: Pfizer Inc is far larger — about 8× SiTime Corporation's market cap, and Pfizer Inc pays a 6.14% dividend while SiTime Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and SiTime Corporation for 18 Days on average.
| PFE | SITM | |
|---|---|---|
Market Cap | $159.59B | $19.99B |
Volume | 30,937,010 | 339,821 |
Sector | Health | Technology |
52-Week High | $29.02 | $901.60 |
52-Week Low | $23.67 | $252.76 |
Typical Hold Time | 158 Days | 18 Days |
Enterprise Value | $211.09B | $19.39B |
Dividend Yield | 6.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
SiTime Corp (SITM) trades at $665.16, down 6.46% today but maintains strong analyst support with 100% buy ratings and a $751.43 consensus price target. The stock shows bullish technical signals with support at $659 and resistance at $678, while recent quarterly earnings consistently beat expectations. Revenue growth accelerated to 126.5% year-over-year in Q2 2026, driven by AI infrastructure demand and the Renesas acquisition, though current valuation metrics remain elevated with P/S at 37.99.
SITM presents significant growth potential as a precision timing specialist benefiting from AI data center expansion, with projected revenue growth and margin expansion. However, risks include high valuation multiples, insider selling activity, and dependence on sustained AI infrastructure spending. The stock's current pullback may offer entry opportunity given strong fundamental momentum and unanimous Wall Street optimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →
